Portal Veterinary medicinal products

12/12/2024 —
News

Determination of the annual coefficient for the revaluation of taxes in 2025

As part of its tasks relating to the assessment and risk management of veterinary medicinal products, ANSES collects taxes and fees. Taxes, with the exception of the annual tax indexed to the turnover of veterinary medicinal products, are revalued annually.
un chat et un chien
18/11/2024 —
News

Antimicrobial resistance in animal health and the sale of antibiotics for veterinary use: 2023 review

To mark European Antibiotic Awareness Day, we are publishing the 2023 results from the monitoring of sales of veterinary medicines and antibiotic resistance of pathogenic bacteria in animals.
Ingestion médicaments chevaux
01/10/2024 —
Daily life

Medication for treating Cushing's disease in horses: risk of accidental human ingestion

Around 60 cases of humans being poisoned by medication containing pergolide intended for horses have been reported since 2012. Because of the small size of the tablets and the long duration of the treatment, the risk of accidental ingestion is particularly high. Here is a reminder of the recommendations for avoiding accidents and taking appropriate action in the event of accidental ingestion.
24/09/2024 —
News

Infectious feline peritonitis: prescription of dispensers' preparations

The availability of GS-441524 by pharmacies has raised questions. The French agency for veterinary medicinal products (ANMV) has long been involved in the issue of the therapeutic gap related to feline infectious peritonitis (FIP), in collaboration with the Monitoring committee for veterinary medicinal products. In particular, it has worked to ensure that the use of Remdesivir is not excluded in veterinary medicine at European level. At the same time, the ANMV informed stakeholders of the various legal gateways to therapeutic solutions, including dispensers' preparations.
09/08/2024 —
News

Senvelgo: risk of ketoacid diabetes associated with the use of the veterinary medicine

SENVELGO® (velagliflozin) 15 mg/ml - oral solution for cats - has been granted a marketing authorisation by the European Commission in November 2023. At the request of the European Medicines Agency and, for France, the National agency for veterinary medicinal products, Boehringer Ingelheim Vetmedica GmbH disseminates information on the occurrence of serious adverse reactions and how to prevent them.
05/06/2024 —
News

The French Agency for Veterinary Medicinal Products celebrates its 30th anniversary

The French Agency for Veterinary Medicinal Products (ANMV) was created in 1994. Part of ANSES, it monitors the efficacy of the veterinary medicinal products used in France and ensures they are environmentally friendly and safe for animal and human health. The ANMV’s missions and importance on the French and European scenes have changed significantly over the past 30 years. Below, Franck Fourès, Director of the ANMV, looks back at its history and discusses the major challenges that lie ahead.
21/03/2024 —
News

Procedures for declaring discontinuations or abandonments of marketing authorisations for veterinary medicinal products in France

Paragraph 13 of Article 58 of European Regulation 2019/06 states that the marketing authorisation holder must inform the competent authorities in advance of any cessation of marketing of a veterinary medicinal product, of the reasons justifying it and of any action he intends to take.
21/03/2024 —
News

Publication of the "Guidance to applicants"

The European Commission published the Guidance to Applicants on 23 February 2024. This guide replaces the "Notice to Applicants volume 6A chapter 1" which no longer has a regulatory basis in the Veterinary Medicinal Products Regulation.
23/02/2024 —
News

Procedures for reporting veterinary medicinal product shortages

The issue of medicinal products supply shortages is a major topic for both animal and human health. In veterinary medicine, the holders or their representative (responsible for placing on the market) are obliged to report to Anses any risk of shortage of a veterinary medicinal product which could lead to a risk to human health, animal health or animal welfare.

Pages